What should you pay attention to during Aila Gokna treatment?

Elagokna causes a dose-dependent decrease in bone mineral density (BMD). The decrease in BMD increases with the duration of medication and may not be completely reversible after discontinuation of treatment. Contraindicated in women with known osteoporosis; consider assessment of BMD in patients with a history of low-trauma fractures or other risk factors for osteoporosis or bone loss. Limit the duration of medication to reduce bone loss.

Women taking Elagokna may experience a decrease in the amount, intensity, or duration of menstrual bleeding, which may reduce the ability to promptly recognize the occurrence of pregnancy, obtain a pregnancy test if pregnancy is suspected, and discontinue Elagokna if pregnancy is confirmed.

Promptly evaluate patients with depressive symptoms to determine whether the risks of continued treatment outweigh the benefits. Patients with new or worsening depression, anxiety, or other mood changes should be referred to a mental health professional as appropriate. If suicidal thoughts and behaviors occur, patients are advised to seek immediate medical attention. If such an event occurs, re-evaluate the benefits and risks of continuing treatment with Elagokna.

Use the lowest effective dose and instruct patients to seek immediate medical attention if they develop signs or symptoms that may reflect liver injury (such as jaundice). Promptly evaluate patients with elevated liver function test results to determine whether the benefits of continued treatment outweigh the risks. In clinical trials, treatment with Elagokna resulted in a dose-dependent increase in serum alanine aminotransferase (ALT) that was at least 3 times the upper limit of the reference range.

Advise female patients to use effective non-hormonal contraceptives during treatment with Elagokna and for 28 days after stopping treatment with Elagokna. It is contraindicated in pregnant women as exposure to Elagokna during the first trimester may increase the risk of early pregnancy loss.

Allegona is contraindicated in patients with severe hepatic impairment, patients with known osteoporosis, patients known to have a hypersensitivity reaction to Allagena or any of its inactive ingredients, and patients using inhibitors of organic anion transporting polypeptide (OATP) 1B1 (hepatic uptake transporter) known or expected to significantly increase Allagena plasma concentrations.

Elagokna can be used to treat moderate to severe pain associated with endometriosis. The above are part of the precautions for Aila Gokna. For more details, you can read the drug instructions. It is recommended that patients follow the doctor's instructions and take the medication and treat it symptomatically.

Recommended related articles: